News Feature | June 4, 2014

Bayer And Orion Collaborate To Develop Prostate Cancer Drug

By Estel Grace Masangkay


Bayer and Orion announced that the companies have entered into a global partnership to develop and commercialize the investigational compound ODM-201 for the treatment of patients with prostate cancer.

ODM-201 is a novel androgen receptor (AR) inhibitor designed to stop the growth of castration-resistant prostate cancer (CRPC). The compound is different from other drugs as it does not enter the brain while blocking AR nuclear translocation in non-clinical models of the disease.

Under the terms of the agreement, the companies will jointly develop ODM-201. Bayer will shoulder the major share of future development costs and will commercialize the compound worldwide. Orion has the option to co-promote the drug in Europe and is eligible to receive substantial royalties on product sales.

Orion and Bayer will jointly start clinical development of ODM-201 to investigate the drug’s efficacy and safety in patients with non-metastatic castration-resistant prostate cancer (nm-CRPC) this year. Orion will be responsible for manufacturing of the ODM-201. As a result of the agreement with Bayer, Orion has updated its full year outlook estimate for 2014.

Dr. Reijo Salonen, SVP of R&D at Orion said the partnership will enable the development of a potential treatment for patients who have prostate cancer, which is the second leading diagnosed malignancy in men around the world. The standard treatment of hormonal deprivation allows long-lasting and effective management of cancer-related symptoms in the disease’s stages. However, in some patients the disease will progress and turn castration-resistant, characterized by persistent and high level AR function. CRPC has also been observed to resist traditional anti-androgens such as bicalutamide.

Dr. Joerg Moeller, Member of the Bayer HealthCare Executive Committee and Head of Global Development, said, “We see in ODM-201 a potential new treatment for patients with high risk non-metastatic castration-resistant prostate cancer and are looking forward to developing this promising compound. From a clinical perspective, ODM-201 has the potential to complement our portfolio in prostate cancer and enables us to deliver new treatment options for patients who desperately need them.”

Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.